HER2 mediates clinical resistance to the KRASG12C inhibitor sotorasib, which is overcome by co-targeting SHP2

K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions

J.M. Ostrem, Ulf Peters, Martin L. Sos et al. · Nature · 2013 · 2.5K citations · Full text

Life Sciences, Molecular Biology, Pharmacology +14

Sotorasib for Lung Cancers with <i>KRAS</i> p.G12C Mutation

Ferdinandos Skoulidis, Bob T. Li, Grace K. Dy et al. · New England Journal of Medicine · 2021 · 1.8K citations · Full text

Medicine, Oncology, Pharmacology +17

The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients

Jill Hallin, Lars D. Engstrom, Lauren Hargis et al. · Cancer Discovery · 2019 · 1.3K citations · Full text

Medicine, Oncology, Pharmacology +17

Acquired Resistance to KRAS ^G12C Inhibition in Cancer

New England Journal of Medicine · 2021 · 1.2K citations · Full text

Medicine, Molecular Biology, Oncology +14

SynergyFinder 2.0: visual analytics of multi-drug combination synergies

Aleksandr Ianevski, Anil K. Giri, Tero Aittokallio · Nucleic Acids Research · 2020 · 948 citations · Full text

Computing, Pharmacology, Visualization +16